p53 counteracts the elevation of glycolytic flux observed in cancer cells through inhibiting the expression of glucose transporters, GLUT1 and GLUT4[42], as well as decreasing the levels of phosphoglycerate mutase 1 (PGAM1), the enzyme responsible for the conversion of 3-phosphoglycerate to 2-phosphoglycerate during glycolysis[43]. The gene discussed is TP53; the disease is cancer.